Overview
Founded in 2020, Genflow Biosciences plc is an emerging leader in longevity research with R&D facilities in Belgium. The company develops novel therapeutic approaches potentially targeting the aging process in humans and dogs, with its lead compound GF-1002 delivering a centenarian variant of the SIRT6 gene identified in individuals aged 100 or beyond.
Key people
In the news
- Did You Know? Companion dogs offer a uniquely relevant model for aging research. They share our environments, develop many of the same age-related conditions, and experience comparable functional decline - while aging more rapidly than humans, allowing interventions to be studied over a compressed timeframe. These positions the #dog as a powerful bridge between preclinical research and human health. Learn more about our research: https://lnkd.in/g9wPWU_T #GENF #GENFF #Aging #SIRT6
- We’re heading to Toronto for the Animal Longevity Summit 2026! Genflow Biosciences (LON:GENF) (OTCQB:GENFF) will present results from our SLAB study, which is examining sarcopenia and longevity in aged beagles. The inaugural #ALOS26 will bring together researchers, veterinarians, biotechnology companies and investors working to advance healthy longevity in animals. #Longevity #Biotech #GeneTherapy #GENF #GENFF
- Want to learn more about Genflow Biosciences (LON:GENF) (OTCQB:GENFF)? Subscribe to our newsletter to stay informed on the latest company updates and developments: https://lnkd.in/easKF3iU
- Looking to learn more about Genflow Biosciences (LON:GENF) (OTCQB:GENFF)? Visit our investor page for the latest company news, regulatory announcements, and presentations as we continue advancing our SIRT6-focused pipeline. 🔗 Explore the investor page: https://lnkd.in/eYJ_AQ3H
- Mark your calendars! Genflow Biosciences (LON:GENF) (OTCQB:GENFF) will be presenting results from our SLAB (Sarcopenia and Longevity in Aged Beagles) study at the Animal Longevity Summit 2026 in Toronto! As the first conference dedicated exclusively to animal longevity, #ALOS will bring together leading researchers, veterinarians, biotechnology companies, and investors focused on extending healthy lifespan. #ALOS26 #Longevity #Biotech #GeneTherapy #GENF #GENFF
- Genflow Biosciences (LON:GENF) (OTCQB:GENFF) has provided an update on progress across its SIRT6 patent portfolio! 🧬 Recent developments include publication of its US patent application covering MASH, Track One prioritized examination for its foundational U.S. SIRT6 patent family and continued progress toward grant of its corresponding European application. Read the full announcement: #GENF #GENFF
- As Genflow Biosciences (LON:GENF) (OTCQB:GENFF) approaches the completion of its SLAB study, external coverage is highlighting our progress across multiple fronts. From sustained observations in aged beagles to its non-dilutive collaboration with Acuitas Therapeutics, the article examines the science and milestones supporting Genflow's #SIRT6 platform. Read the full feature: https://lnkd.in/eb3pFG-e #Genflow #GENF #GENFF #Longevity #Biotech
- Recognition continues to build around Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s work in longevity science! A recent feature explores our #SIRT6 platform, sustained observations from the SLAB study, expanding #IP portfolio and collaboration with Acuitas Therapeutics as Genflow continues to advance its pipeline. Read the full article: https://lnkd.in/eb3pFG-e #Genflow #GENF #GENFF #Longevity #Biotech #GeneTherapy
Something wrong or missing? Send an update. Fixed within 24 hours.